RPE65-related retinal dystrophy: mutational and phenotypic spectrum in 45 affected patients | medRxiv
Gene Therapy Restores Vision-Dependent Behavior as Well as Retinal Structure and Function in a Mouse Model of RPE65 Leber Congenital Amaurosis: Molecular Therapy
CRISPR-Cas9–mediated therapeutic editing of Rpe65 ameliorates the disease phenotypes in a mouse model of Leber congenital amaurosis | Science Advances
RPE65 - an overview | ScienceDirect Topics
A New Gene Therapy For Early-onset RP
LUXTURNA® Mode of Action | LUXTURNA® HCP
AZ RETINA Project on Twitter: "This happens by restoring the missing enzyme in RPE. The treatment is injected past the neural retina, so it interacts with the RPE. Recently, there has been
LUXTURNA® Mode of Action | LUXTURNA® HCP
![Figure 1, [Visual Cycle]. - CADTH Issues in Emerging Health Technologies - NCBI Bookshelf](https://www.ncbi.nlm.nih.gov/books/NBK538375/bin/eh0067_voretigene_neparvovec_emerging_healthf1.jpg "Figure 1, [Visual Cycle]. - CADTH Issues in Emerging Health Technologies - NCBI Bookshelf")
Figure 1, [Visual Cycle]. - CADTH Issues in Emerging Health Technologies - NCBI Bookshelf
RPE65 - Wikipedia
Gene therapy: 'Now I can see my own face again' - BBC News
Gene therapy - Gene Vision
The gene therapy revolution in ophthalmology - ScienceDirect
A Novel Mutation in the RPE65 Gene Causing Leber Congenital Amaurosis and Its Transcriptional Expression In Vitro | PLOS ONE
Gene Therapy & Clinical Trials to Treat Vision Loss | Fighting Blindness Canada
New gene therapy saves the sight of children with eye disease - The University of Sydney
RPE65 Gene Therapy: A Report From the Clinic - American Academy of Ophthalmology
Genes | Free Full-Text | Properties and Therapeutic Implications of an Enigmatic D477G RPE65 Variant Associated with Autosomal Dominant Retinitis Pigmentosa
A New Gene Therapy For Early-onset RP
Gene therapy for RPE65-mediated inherited retinal dystrophy completes phase 3 - The Lancet
Frequency and phenotypic characteristics of RPE65 mutations in the Chinese population | Orphanet Journal of Rare Diseases | Full Text
Long-Term Structural Outcomes of Late-Stage RPE65 Gene Therapy: Molecular Therapy
The interplay of environmental luminance and genetics in the retinal dystrophy induced by the dominant RPE65 mutation | PNAS
Persistence of non-viral vector mediated RPE65 expression: Case for viability as a gene transfer therapy for RPE-based diseases - ScienceDirect
